Michael ArtingerManaging Director - Research Translation Group, UCI Applied Innovation

Artinger’s expertise includes an in-depth knowledge of company formation, equity, and grant fundraising, as well as mergers and acquisitions. He earned a doctorate degree in developmental & cell biology, bachelor’s degree in applied ecology from UCI, and completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital


Frances A. Ayalasomayajula, Global Healthcare Solutions Industry Solutions Organization, HP Inc. 

For over 20 years, Fran Ayalasomayajula, D. Msc., executive healthcare strategist and technologist, has been dedicated to serving the interests of populations around the world in an effort to improve the quality of healthcare, provision access to healthcare, and increase health literacy and patient engagement.

Currently the Global Healthcare Solutions Senior Manager for HP, Inc., Fran leads the organization in devising strategies and innovations designed to advance and deliver improved clinical outcomes and better population health. Prior to HP, Fran worked for major healthcare institutions, including WHO, CDC, BMS, and UHG. Fran holds degrees in epidemiology, public health, information technology, and certification in project and clinical trial management.

She is actively involved in community minded initiatives, such as rare disease patient advocacy, and the application of technology services for the promotion of aging with independence and community connectedness. In 2015, Fran was a contributing writer on the Fact Sheet submitted to the White House Conference on Aging and the 2017 LeadingAge whitepaper on Social Connectedness and Engagement Technology for Long-Term and Post-Acute Care. She is presently a Board Member of NHA of San Diego, member of the Center on Aging Services and Technologies, PCHAlliance, LeadingAge, APHA, special interest participant in the NAHC, and founder of IBHealthy, a 501(c)3 nonprofit digital health and wellness club, whose mission is to provide ease of access to the resources needed to adopt and maintain a healthy lifestyle.


Bill Ayers, Director, Health Care Advisory Services, RSM US LLP

Bill has over 25 years of health care and consulting executive leadership experience with a comprehensive and vast blend of expertise in health care revenue cycle management (RCM), provider revenue integrity/reimbursement strategy, accounts receivable (A/R) management, cash acceleration, revenue cycle transformation and optimization, health care RCM IT, clinical documentation improvement (CDI), patient access/experience, clinical transformation (CT) and revenue metrics reporting, as well as overall health care delivery experience. He has been engaged in a multitude of health care sub-sectors, including health care providers, life science and pharmaceutical firms, health care payers and managed care organizations, medical imaging firms, durable medical equipment manufacturers and suppliers, health care and life science service and content providers, financial services organizations and ancillary health care service and delivery providers. 

Prior to joining RSM, Bill directed and led the RCM and CT practices for a nationally known health care provider IT and transformation consulting firm serving large and mid-sized IDNs, academic medical centers and community hospitals/providers, as well as other types of health care delivery providers. A former Big Four consultant, he has led, directed and managed many large end-to-end RCM transformation and optimization projects nationwide. Bill has IT experience in a variety of RCM and CT platforms, including Epic, Cerner, MediTech, Allscripts, NextGen, McKesson and Soarian, as well as many other applications. In addition, his teams have been responsible for successfully assisting many health care providers with achieving and maximizing expected and anticipated revenues while improving operating margins in an effort to maintain the best operational efficiencies for the clients he has served.  


Ron Bache, President & CEO, Bache, Inc. 

Ron Bache is currently the CEO of Bache, Inc., an Allergan Special Advisor, and an Operating Partner with the private equity firm Invus Opportunities.  Bache advises startups and large multinational corporations on winning with amazing teams and technologies through focus, alignment, clear strategy, relentless execution, and always finding a way to overcome obstacles.  

Bache is the former President and CEO of AqueSys, a venture capital backed medical device company which developed the XEN Gel Stent (acquired by Allergan). Prior to AqueSys, Ron was a Global Vice President at Advanced Medical Optics (acquired by Abbott), and has over 23 years of experience in the pharmaceutical and medical device industry. 


Brendan Benner, Vice President Regulatory Affairs, MDMA

Brendan Benner is the Vice President of Public Affairs for the MDMA where he is in charge of communications, strategic outreach and grassroots development. Benner has extensive experience in the private and public sector, as well as working with non-profits. He began his career with the Archdiocese of Philadelphia's Office of Public Affairs where he worked on education policy and other issues, interacting with elected officials and policy makers. He spent several years working in Congress, serving both as a Communications Director and District Director for former Congresswoman Melissa Hart (PA) and Congressman Jim Gerlach (PA) respectively. He oversaw and implemented aggressive media and outreach plans in these highly competitive congressional districts. Mr. Benner is also a veteran of numerous Congressional and Presidential campaigns as well. Mr. Benner is a member of the Pennsylvania Bar and a graduate of Georgetown University and Temple University's Beasley School of Law. 


Chris Calcaterra, Chief Operating Officer, Glaukos

Mr. Calcaterra has served as chief operating officer since February 2017. He was previously the Chief Commercial Officer, a position he had held since joining Glaukos in April 2008. Mr. Calcaterra has 30 years of experience in the ophthalmic medical technology industry. Prior to joining Glaukos, Mr. Calcaterra was Senior Vice President at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), and was responsible for its cataract business. Prior to that position, Mr. Calcaterra held increasingly responsible vice president positions in a variety of sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division business at Allergan, Inc. Mr. Calcaterra has a BS from Miami University and an MBA from Xavier University. 


Cavan Canavan

Cavan is the CEO and cofounder of Santa Monica-based FocusMotion, a machine learning software company dedicated to improving human motion analysis and quantification through wearable and IOT devices. FocusMotion’s mission is to become the centralized motion recognition and insight platform to empower the emerging ecosystems of health and fitness wearable developers. They have been tapped by some of the biggest brands in wearables including Microsoft, Wearable Experiments, Lululemon, and Samsung for its unique algorithmic technology that can identify, track, and quantify human movement. Cavan’s professional background spans multiple disciplines including product design and development and corporate rebranding. He has a history of disruption, invention and innovation, applying his expertise at market-leading, global companies such as Apple, Vans and New Balance. 


Bill Carpou, CEO, OCTANe

Bill Carpou is the chief executive officer of OCTANe. Prior to joining OCTANe as CEO, Mr. Carpou served as an operating partner at the private equity firm, Blackstone including leading a key portfolio company, RGIS.  Mr. Carpou was recruited to this position by Blackstone and was responsible for all aspects of revenue including sales, marketing, channel expansion, strategic alliances, acquisitions and customer service. 

Mr. Carpou’s prior experience includes a stint as a partner at Profit Recovery Partners (“PRP”).  Before joining PRP, Mr. Carpou served in a variety of senior executive positions at IKON Office Solutions for 18 years where he led revenue and M&A activities for a variety of key areas within IKON’s global operations.  IKON has since been acquired by Ricoh Corporation. He began his career with the Xerox Corporation and earned his securities license at Merrill Lynch. 

Mr. Carpou has a bachelor’s degree in marketing from Villanova University.  He has served on the board of the Barclay Theatre, serves on the Dean’s Advisory Board at the Villanova School of Business and is a member of the Chief Executive Roundtable at the University of California, Irvine.  He resides in Laguna Niguel, California.


Albert Cha, MD, PhD, Managing Partner, Vivo Capital

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), Carbylan Therapeutics (NASDAQ: CBYL), and several private companies. 

He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. 

 


Ravi Chana, Sector Specialist- MedTech, Department for International Trade

After completing a degree in Pharmacology Ravi gained employment in sales roles in non-health related fields for 4 years. He then worked in the Healthcare Industry for over 15 years, undertaking sales, marketing, business development and heading the Health Economics and Market Access function within a Multinational Diagnostics Company. He has actively participated in a number of working groups within the National Institute of Health and Care Excellence (NICE) and the British In-Vitro Diagnostics Association (BIVDA). His role as Business Development Manager at the NIHR Office for Clinical Research Infrastructure (NOCRI) has enabled him to gain experience in working with the UK Department of Health in setting up and leading MedTech and Diagnostics Clinical Research Infrastructure. He has worked closely with leading Academic and Clinical Experts within world-leading Research Institutions and NHS Trusts to initiate collaborations with Life Science companies. The role has also provided knowledge of UK market access, helping companies to navigate the complex UK NHS landscape. In 2017 Ravi also took on the role of Sector Specialist–MedTech at the Department for International Trade. In this role, with the help of his Network of experts, Ravi provides support to UK MedTech companies to engage in trade opportunities outside of the UK, and support Non-UK MedTech companies access the UK market.


Anthony Chang, Chief Intelligence Officer, CHOC

Dr. Chang attended Johns Hopkins University for his B.A. in molecular biology prior to entering Georgetown University School of Medicine for his M.D. He then completed his pediatric residency at Children’s Hospital National Medical Center and his pediatric cardiology fellowship at Children’s Hospital of Philadelphia. He accepted a position as attending cardiologist in the cardiovascular intensive care unit of Boston Children’s Hospital and as assistant professor at Harvard Medical School. He has been the medical director of several pediatric cardiac intensive care programs (including Children’s Hospital of Los Angeles, Miami Children’s Hospital, and Texas Children’s Hospital). He is currently the Chief Intelligence and Innovation Officer and Medical Director of the Heart Failure Program at Children’s Hospital of Orange County. He has also been named a Physician of Excellence by the Orange County Medical Association multiple years. He has completed a Masters in Business Administration (MBA) in Health Care Administration at the University of Miami School of Business and graduated with the McCaw Award of Academic Excellence.

He also completed a Masters in Public Health (MPH) in Health Care Policy at the Jonathan Fielding School of Public Health of the University of California, Los Angeles and graduated with the Dean’s Award for Academic Excellence. He recently completed his Masters of Science (MS) in Data Science with a sub-specialization in artificial intelligence from Stanford School of Medicine. He is also a computer scientist- in-residence at Chapman University. He is known for several innovations in pediatric cardiac care , including introducing the cardiac drug milrinone and co-designing (with Dr. Michael DeBakey) an axial-type ventricular assist device in children. He has helped to build a successful cardiology practice as a company and was able to complete a deal on Wall Street.

He is a committee member of the National Institute of Health pediatric grant review committee. He is also the editor of several textbooks in pediatric cardiology, including Pediatric Cardiac Intensive Care, Heart Failure in Children andYoung Adults , and Pediatric Cardiology Board Review. He is the founder of the Pediatric Cardiac Intensive Care Society (PCICS) that launched the multi-disciplinary focuses on cardiac intensive care for children.

He is also the founder of the Asia-Pacific Pediatric Cardiac Society (APPCS) , which united pediatric cardiologists and cardiac surgeons from 24 Asian countries  and launched a biennial meeting in Asia that now draws over 1,000 attendees. He is the founder and medical director of the nascent Medical Intelligence and Innovation Institute (MI3) that is supported by the Sharon Disney Lund Foundation. The institute is dedicated to implement data science and artificial intelligence in medicine and is the first institute of its kind in a hospital. The new institute is concomitantly dedicated to facilitate innovation in children and health care all over the world. He is the organizing chair for the biennial Pediatrics2040: Emerging Trends and Future Innovations meeting as well as the founder of the Medical Intelligence and Innovation Summer Internship Program, which mentors close to 100 young physicians-to-be every summer. He has organized a pediatric innovation leadership group and has started the international Society for Pediatric Innovation (iSPI). He intends to build a clinician-computer scientist interface to enhance all aspects of data science and artificial intelligence in health and medicine. He currently lectures widely on big data and artificial intelligence in medicine (he has been called “ Dr. A.I. ” and has given a TEDx talk and on the faculty of Singularity University) (1). He has also published review papers on big data and predictive analytics as well as machine learning and artificial intelligence in medicine (2 )(3). He is currently organizing a book project and an international meeting, Medical Intelligence: Big Data, Predictive Analytics, Cognitive Computing, Deep Learning and Artificial Intelligence in Medicine .He is also the Co -founder and CEO of a startup company (CardioGenomic Intelligence, LLC ) that focuses on artificial intelligence applications such as deep learning in clinical cardiology and genomic medicine


Nigel Clarke, VP of R&D, Quest Diagnostics

Dr Nigel Clarke received his PhD in mass spectrometry and analytical chemistry from the University of Kent at Canterbury
in England, and completed postdoctoral fellowship training in biomedical mass spectrometry at the Mayo Clinic in Rochester, MN. He was a principle investigator at the Schering-Plough Research Institute in Kenilworth, NJ, where he ran the drug discovery metabolite identi cation group and worked at ActivX Biosciences (a biotechnology company) as director of mass spectrometry before joining Quest Diagnostics Nichols Institute.  

Dr Clarke is involved in several academic collaborations with groups at multiple sites, including Cedars-Sinai, the CDC and Massachusetts General Hospital and UCSF, utilizing the LC-MS/MS assays he and his group have developed to create and re ne standardized reference ranges for both clinical studies and diagnostic usage.  He has published widely on his use of mass spectrometry in a variety of biological arenas, is a reviewer for multiple journals, and received multiple awards, including the Michael Barber Award for Mass Spectrometry, The President’s Award for Discovery from the Schering-Plough Research Institute, and the Medical Innovations Award from Quest Diagnostics.  

 


Andy Corley, Founder, Yelroc Consulting & Co-Founder, Flying L Partners

Mr. Andy Corley serves as Senior Consultant to Bausch and Lomb. Mr. Corley serves as Venture Partner at One Focus Ventures. He co-founded eyeonics, Inc. in 1998. Mr. Corley spearheaded a 5-year effort to change CMS policy to allow Medicare beneficiaries a choice in their selection of intraocular lenses associated with cataract surgery. Mr. Corley served as the President of the Surgical Division at Bausch and Lomb. He co-founded Chiron Ophthalmics, where he served as a General Manager of Refractive Surgery Division until 1997. At Chiron, he played a key role in the introduction of LASIK. In 2005, he was the Orange County Entrepreneur of the Year. In 2011, Mr. Corley formed Yelroc Consulting Inc. He serves as Chairman of the Board of Technolas Perfect Vision. He served as Executive Chairman of NeoVista Inc. Mr. Corley serves as the Chairman at Calhoun Vision, Inc. He has been a Director of ReVision Optics, Inc. since January 22, 2016. He serves on the advisory boards of the UCI School of Biomedical Engineering and the Scripps Genomic Institute. He is a Graduate of Georgia Southern University. 


Brian Cox, Co-Founder, Sequent Medical; Vice President, Inceptus Medical

Brian Cox has worked in various R&D, clinical research, marketing and management position in medical devices over the last 34 years.  Brian is currently Vice President and one of the co-founders of Inceptus Medical, LLC a medical device incubator founded in June 2011.  Brian is also a Vice President and co-founder of Inari Medical Inc.  Inari is the first company created by Inceptus. Prior to Inceptus, he was a founder of Sequent Medical. Brian served as Vice President/CTO since the Company's founding. During that time, Brian led the Sequent team in developing the Company’s initial technology platform from concept through preclinical testing, and on to successful initial human use and CE mark. Prior to Sequent, Brian was a founder of MicroVention and served as Vice President of Business and Technology Development. Prior to MicroVention, Brian was Engineering Manager at Medtronic AneuRx, Inc. Prior to AneuRx, he held various managerial and technical positions with Advanced Surgical Intervention, Inc., Allergan Medical Optics, and Shiley. He earned a B.S. in mechanical engineering from Oregon State University and a M.B.A. from Pepperdine University. Brian is an inventor on over 50 issued U.S. and international patents. 

 


Louis Cullman, Partner, K&L Gates

Mr. Cullman a partner in the Orange County office of K&L Gates LLP specializing in intellectual property (IP) law where he manages the transactional IP group. His practice has a strong life sciences focus and concentrates on transactional IP for pharmaceutical and medical device companies including patent procurement, technology transfer and Bayh-Dole issues, merger and acquisition-related due diligence, freedom to operate analyses, non-infringement and invalidity opinions, Hatch-Waxman-related client counseling and litigation support. Mr. Cullman regularly represents pharmaceutical and medical device companies including Allergan, Baxter Biosciences, Beckman Coulter, Medtronic and Spectrum Pharmaceuticals in matters related to product life cycle management, patent litigation strategy and merger and acquisition IP due diligence. Prior to attending law school Mr. Cullman was a licensed Clinical Microbiologist and co-founded and directed an infectious disease laboratory and diagnostic device manufacturing company in Southern California. He has extensive technical experience in the design and manufacturing of in vitro diagnostic devices for infectious diseases, immunology and biochemistry.


Jim Doti, Professor & President Emeritus, Chapman University

James Doti earned his B.S. degree in economics from the University of Illinois, Chicago, and his M.A. and Ph.D. degrees from the University of Chicago.  

He was appointed president of Chapman University in 1991 and served for 25 years.  In September 2016, he returned to the Chapman faculty.  He holds the Donald Bren Distinguished Chair in Business and Economics. 

Dr. Doti joined the Chapman faculty in 1974.  In 1978, he founded the A. Gary Anderson Center for Economic Research to provide data, facilities and support to encourage faculty and students to engage in research of high quality, and to widely disseminate the results.  The Center’s inaugural Orange County Forecast, presented in December 1978, was the first economic forecast in the U.S. to be based on an urban econometric model.  

The Economic Forecast has continued to be a main focus of the Anderson Center’s work, growing in scope and widely recognized for its statistical accuracy.  Over the 2004 through 2014 period, Chapman’s real GDP forecasts were more accurate than the forecasts issued by all 30 agencies participating in the Blue Chip Economic Indicators surveys.  The Chapman forecast model also outperformed the highly regarded Blue Chip Consensus forecast. 

Dr. Doti’s articles have appeared in academic journals as well as periodicals such as The Wall Street Journal and The Chronicle of Higher Education.   His frequent op-eds appear in the Orange County Register, and he is a regular columnist for Orange County Business Journal.  He is also the co-author of two econometrics texts and co-editor of a collection of readings in free enterprise that received the Templeton Honor Award for Scholarly Excellence.  

Dr. Doti is a recipient of the Horatio Alger Award and the Ellis Island Medal of Honor.  

He has completed 60 marathons and climbed five of the world’s famed Seven Summits. He is also an avid reader and writer.  His first children’s book, A Christmas Adventure in Little Italy, was published in 2010 and became a Sons of Italy Book Club selection.  His second, Jimmy Finds His Voice, came out in January 2013.  The final installment of the “Jimmy Trilogy,” I Love You This Much, Nonna, is forthcoming in 2017. 


Spencer Hamer, Partner, K&L Gates

Spencer Hamer focuses his practice on labor and employment matters including wage and hour, discrimination, harassment, executive agreements, leaves of absence, disability, retaliation, unfair competition, trade secrets, wrongful termination, privacy rights, and the National Labor Relations Act. Mr. Hamer has successfully represented employers in numerous cases in state and federal court. In addition, his practice involves management training, compliance audits, employment policies and procedures, workplace investigations, and risk management strategies. Mr. Hamer has represented employers in a variety of industries, including health care, hospitality, manufacturing, advertising, digital media, and education.


Michael Hedge, Administrative Partner, K&L Gates

Michael Hedge is a partner in the firm's Orange County office. His practice focuses on securities, mergers and acquisitions, corporate finance, venture capital, corporate governance and commercial transactions. Mr. Hedge has extensive experience in representing public companies in securities offerings, mergers and acquisitions and stock exchange compliance matters. Mr. Hedge also regularly works with private equity funds in acquisition transactions and fund formation. Mr. Hedge has substantial experience in the medical device, pharmaceutical and technology industries


Doug Holte, President, Office Spaces, Irvine Company

Doug Holte is President of Irvine Company Office Properties. In his position, Mr. Holte is responsible for the overall performance of the Irvine Company’s portfolio of office properties in Orange County, San Diego, West Los Angeles, Bay Area, Chicago and New York. These responsibilities include supervision of leasing, operations, marketing, design, development and acquisition of office properties. Mr. Holte joined the Irvine Company in 2009 after a 22-year career as a principal in development, investment and asset management with the international real estate firm Hines. During his Hines career, Mr. Holte has been responsible for more than 15 million square feet of office development, property acquisition and third-party client service assignments throughout the West Coast and Southeast regional markets. Mr. Holte is on the Advisory Council for the USC Lusk Center for Real Estate, and a Board Chair for the Orange County Community Foundation. He is a graduate of University of Southern California and received his Masters of Business Administration from Harvard University


David Hood, President & CEO, DH3 & Associates

Dave D Hood is President and CEO of DH3 & Associates, a consulting company focusing on performing technology assessments and developing strategies for product development and business development. Emphasizing the pursuit and capture of non-dilutive funding coupled with institutional and strategic investors. Expertise and experience with intrapreneurship, entrepreneurship, product development, project/program management, business management and business development. Helping companies work with the government –particularly the military/DOD. Highly regarded as a subject matter expert. Frequent invited speaker at various academic and industry venues domestic and international. For more than five years, Mr. Hood also served as a Senior Advisor for the Principal Assistant for Acquisitions at the US Army Medical Research and Material Command. Prior to founding DH3 & Associates, Mr Hood was the Co-Founder and President of Integrated Medical Systems where he was also co-inventor of the company’s core product line. Prior to being selected to guide this successful spin-out from Northrop Grumman, he served as a Senior Program Manger successfully guiding the development and deployment of various integrated sensor systems for high performance aircraft, missiles, and satellites including the stealth bomber and the Global Positioning Satellites (GPS). He also guided successful projects pioneering intelligent transportation systems and high performance fuel efficient, environmentally friendly engines and brake systems for automobiles and motorcycles.

Mr. Hood has worked with the US Congress and European governments to sponsor funding for innovative products. He holds 3 patents and has been the stimulus for more than 2 dozen. He has published and presented extensively in the US and Europe. He taught graduate school courses in Project Management, Business Management, Operations Management and Entrepreneurship. He is a certified Project Management Professional and has received executive training from the University of Southern California and the Massachusetts Institute of Technology. He is also a past Chairman of the Long Beach Sailing Foundation, a 501c organization that owns a fleet of matched sailboats used for team building experiences as well as amateur and professional racing events including the Congressional Cup. The Foundation also provides inner city and disadvantaged teenagers an opportunity to learn the fundamentals of teamwork and sportsmanship. He is also a board member for the US Sailing Center providing sailing opportunities for disabled children and adults.


Balraj Kakkar, Partner, Life Sciences EY

Balraj Kakkar is a Partner in EY’s Life Sciences practice with 20+ years of experience in life sciences, health care and policy. He supports global bio-pharmaceutical companies in developing growth strategies at the enterprise, franchise and portfolio level, and drive innovation across a range of therapeutic areas. Over the last decade, he has been advising clients on organization re- design, M&A and licensing and go-to-market strategies to enable the transition from a mass-market primary care business to a largely specialty business. He has led teams that supported the successful launch of 10+ specialty products and helped clients expand their presence across multiple geographies (US, EU, Asia & Middle East). Balraj started his pharmaceutical career at Bristol Myers Squibb where he held various roles in Business Development, Marketing and Market Research. Balraj earned an MS in Decision Sciences from Drexel University and an MBA from the Stern School of Business at New York University


Shoshannah Katz, Partner, K&L Gates

Ms. Katz practices in the areas of securities, mergers and acquisitions, finance and general corporate matters, focusing on providing day-to-day client support and coordination of governance issues, transactional needs and specialty counsel. She advises private and public companies in connection with raising capital and issuing securities, compliance with corporate and securities laws and corporate governance practices, debt financing, and negotiation and documentation of a wide variety of corporate and commercial transactions.  Ms. Katz has significant leadership experience in coordination, negotiation and documentation of equity and debt financings for early stage and mature private companies; private and public company mergers, asset acquisitions, stock purchases, and tender offers; PIPEs and public offerings (including IPOs and shelf offerings), representing issuers, placement agents and underwriters; preparing filings for and negotiating with the SEC, FINRA and national securities exchanges; and assisting publicly traded companies with periodic reporting requirements, Sarbanes-Oxley compliance and going private/going dark.  Ms. Katz also provides substantial client support through coordination of specialty counsel in tax, employment (guidance, benefits and litigation), intellectual property, litigation, antitrust and international matters, and advising on clients' post-closing contractual compliance and post-acquisition integration efforts.  Ms. Katz works with companies in a variety of industries, such as food and beverage, medical technology, telecommunications, internet-based services, alternative energy, financial services, auto electronics and insurance.


 

Omar Ishrak, CEO, Medtronic

Omar Ishrak has served as Chairman and Chief Executive Officer of Medtronic since June 2011. Medtronic is the world’s leading medical technology company, with $29 billion in annual revenue, and operations reaching more than 160 countries worldwide. Medtronic offers technologies and solutions to treat a wide range of medical conditions, including cardiac and vascular diseases, respiratory, neurological and spinal conditions, diabetes, and more. The Medtronic Mission is to alleviate pain, restore health, and extend life for millions of people around the world. 

Since joining Medtronic, Omar has focused the company on three core strategies of Therapy Innovation, Economic Value and Globalization. These three strategies form the basis for Medtronic’s efforts to partner with its customers to drive high quality patient outcomes, expand patient access to healthcare, and lower costs in health care systems around the world. In 2014, Omar engineered the acquisition of Covidien, a $10 billion global manufacturer of surgical products and supplies. The acquisition of Covidien was the largest medical technology acquisition in the history of the industry. 

Omar joined Medtronic from General Electric Company, where he spent 16 years, most recently as President and CEO of GE Healthcare Systems, a $12 billion division of GE Healthcare, with a broad portfolio of diagnostic, imaging, patient monitoring and life support systems. Omar also served as an Officer and a Senior Vice President of GE.  Earlier in his career, Omar amassed 13 years of technology development and business management experience, holding leadership positions at Diasonics/Vingmed, and various product development and engineering positions at Philips Ultrasound.  

He grew up in Bangladesh, and earned a Bachelor of Science degree and Ph.D. in Electrical Engineering from the University of London, King's College.  

Omar currently serves as co-chair of the World Economic Forum’s Health and Healthcare Community, which includes global leaders focused on shaping the future of health and healthcare. Key areas of focus for this community include promoting healthy behaviors, better management of future pandemics/epidemics, increasing global access to care, and increasing value in healthcare systems to advance healthcare delivery and improve patient outcomes.  

Omar is a member of the Board of Directors of Intel, a global technology company with more than $59 billion in annual revenue. Omar is a member of the Board of Trustees of the Asia Society, the leading educational organization dedicated to promoting mutual understanding and strengthening partnerships among peoples, leaders and institutions of Asia and the United States in a global context. He is also a member of the Minnesota Public Radio Board of Trustees.  


Jeffrey Kimbell, President, Jeffrey J. Kimbell & Associates

Jeffrey J. Kimbell, President of Jeffrey J. Kimbell & Associates, represents clients in the life sciences community seeking legislative remedies for their needs. Mr. Kimbell specializes in representing life science companies before the U.S. government. The firm provides strategic solutions to hand-selected clients seeking creation, modification, or proper implementation of public law. Three years after establishing his firm, in January of 2001, Mr. Kimbell was named to President George W. Bush’s Transition Team Advisory Committee for the U.S. Department of Health and Human Services (HHS). He was the only consultant to serve on the Committee. 

Prior to establishing Kimbell & Associates, Mr. Kimbell served as the first Executive Director of the Medical Device Manufacturers Association (MDMA) from 1994-1998. While at MDMA, he directed all Washington policy initiatives on behalf of MDMA’s member companies. During his tenure, the association grew from 25 companies to 130, an increase that can be directly attributed to a number of legislative victories, including passage of a landmark bill to overhaul the product approval process at the U.S. Food & Drug Administration.In addition to the handling matters before the U.S Congress, Mr. Kimbell was also responsible for MDMA’s interaction with state and foreign governments and federal agencies of jurisdiction on tax and trade matters. In this capacity, he worked very closely with both the U.S. Department of Commerce and U.S. Trade Representative (USTR). As the principal spokesperson for MDMA, Mr. Kimbell coordinated all communications with the media; the public and private financing communities on Wall Street and related venture capital firms; the U.S. Congress; the White House; HHS; and the FDA. 

Prior to MDMA, Mr. Kimbell was a personal aide to former Senator Howard H. Baker, Jr. (R-TN) and personal attaché to former Secretary of State Lawrence S. Eagleburger in the Washington office of the Tennessee-based law firm Baker, Worthington, Crossley & Stansberry. While at Baker-Worthington, Mr. Kimbell tracked legislative activity for a host of Fortune 500 clients. 

In June 2006, The Hill recognized Mr. Kimbell as one of the top lobbyists in the medical device field in its “Lobby League.” Mr. Kimbell has contributed to or been interviewed by a host of trade and global news publications and television programs: Bloomberg’s Business News, Bureau of National Affairs (BNA), Congressional Quarterly, Forbes, The New York Times, MX Magazine (also serving on their editorial board), Scripps-Howard, Reuters, Time, The Washington Post, Roll Call, Politico, The Food & Drug Law Journal, and many others. Mr. Kimbell has testified before the U.S. Congress and spoken before numerous industry groups, associations, and educational institutions, including within the last year: Harvard Business School, OCTANe Medical Device & Investor Forum, AAOS Chicago Ophthalmology Summit (ACOS), and Columbia University. 

In addition to Jeffrey J. Kimbell & Associates, Mr. Kimbell is Managing Director of Jackalope Real Estate, LLC (Park City, UT) and President of Magnum Entertainment Group, Inc. (Washington, D.C.). 

A graduate of Southern Methodist University (SMU) in Dallas, TX, Mr. Kimbell earned his B.A. in Political Science. While at SMU, he worked for U.S. Congressman Sam Johnson (R-TX), a member of the House Ways & Means Committee, which has jurisdiction over tax, trade, and a significant portion of Medicare. 

Mr. Kimbell is an avid sportsman; fly fishing, hunting, and skiing at locales throughout the world when U.S. Congress is in recess. Mr. Kimbell serves as Chairman of the Safari Club International (SCI) Political Action Committee (SCIPAC), Chairman of the SCI Hunter’s Defense Fund (HDF), and sits on the SCI Government Affairs Committee. 


Barry Kuppermann, Chair- Department of Ophthalmolgogy & Director- Gavin Herbert Eye Institute, UCI

Dr. Baruch Kuppermann is Roger F. Steinert Professor and Chair of the Department of Ophthalmology and Director of the Gavin Herbert Eye Institute, University of California, Irvine, USA. Dr. Kuppermann also holds a joint appointment with the UCI Department of Biomedical Engineering. Dr. Kuppermann’s laboratory research focuses on assessing the toxicity of drugs on retinal cells in culture. He is involved in many multicenter clinical drug trials as a principal investigator evaluating new drugs for the treatment of retinal diseases, and has served as the national leader of numerous multicentered clinical trials. Dr. Kuppermann is an active teacher and lecturer, and is the director of the UCI retina fellowship program. He has published over 200 articles in the medical literature, and over 50 book chapters. Dr. Kuppermann is a highly regarded clinician and surgeon. He has an active clinical practice focusing on the treatment of retinal conditions such as diabetic retinopathy and age-related macular degeneration, as well as surgical conditions such as retinal detachments, macular holes, and epiretinal membranes. Dr. Kuppermann sees patients at the Gavin Herbert Eye Institute in Irvine and the Pavilion II at UCI Medical Center in Orange


Michael Lawlead, Shareholder, Stradling

Michael L. Lawlead is a shareholder in Stradling's Corporate and Securities department, chair of the firm's Digital Health practice group, and a member of the firm's Life Science practice group. Mike's practice focuses on capital markets, venture capital, mergers and acquisitions, and general public and private company representation. He represents digital health, diagnostics, medical device, pharmaceutical, healthcare services and technology companies and investors in a broad range of corporate transactional matters, including formation matters, venture capital financings(including equity and debt),mergers and acquisitions, and public offerings of equity and debt securities. In addition, he advises both public and private companies on general corporate compliance, corporate governance matters and SEC compliance.


Sabing Lee, Partner, Knobbe Martens

Sabing H. Lee is a partner in the Orange County office of Knobbe, Martens, Olson & Bear, LLP. Mr. Lee received his bachelor’s degree in Materials Engineering, Phi Beta Kappa and summa cum laude, from UCLA, and also received his master’s degree in Materials Science and Engineering from UCLA. He received his J.D. from the University of California, Berkeley School of Law (Boalt Hall), where he was an Articles Editor and Executive Editor for the Berkeley Technology Law Journal.

Mr. Lee’s practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, interferences and post-grant proceedings. Mr. Lee currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science. In the medical device field, Mr. Lee has worked extensively with cardiovascular, orthopedic, wound care and aesthetic technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge (acquired by Medtronic), Flex-Foot (acquired by Össur), Endius (acquired by Zimmer Holdings), ev3 (acquired by Covidien), IDev Technologies (acquired by Abbott), Tornier (merged with Wright Medical Technologies) and CardiAQ Valve Technologies (acquired by Edwards Lifesciences).

Mr. Lee currently serves on the Board of Directors for OCTANe, and has been selected for inclusion in the“Southern California Super Lawyers” list from 2013-2017 by Super Lawyers magazine for his work in intellectual property law.


Gerald Lenstra, Netherlands Enterprise Agency

Gerard Lenstra (1964) joined NOM, Investment & Development Agency for the Northern Netherlands as Business Developer in 1998 and is since 2007 responsible for NOM’s Life Sciences & Health activities. NOM is a regional, government-based organization working on enhancement of the northern region’s strengths. Within Life Sciences & Health, the Northern Netherlands focuses on Healthy Ageing. NOM operates closely together with the University Medical Centre in Groningen and the several research institutes and companies.

Gerard Lenstra brings more than 25 years of business experience. He has worked with a variety of companies and institutions helping them to de develop coherent business strategies. He started his career as consultant at Tebodin Consultants & Engineers, advising both companies and the regional and national governments.Gerard Lenstra is member of the advisory board of SPRINT, a Centre of Research Excellence founded with an aim towards senior citizens regaining or improving their mobility.

Between February 2016 and August 2017, he was chair of the supervisory board of Quisper, a scientific platform that aims to facilitate research and development in the field of health, nutrition and wellbeing and to develop scientifically based products and services in the field of personalized nutrition.

From March 2016 on, he was the driving force behind a unique combination of Pharma Portal Groningen and the early stage investment fund Pharma Connect Capital that was launched in October 2017. Gerard Lenstra has a background in Public Administration (Economics, Political Science and Law) at the University of Twente, and in Business Administration at the Open University in The Netherlands.


Ian Liao, Partner, K&L Gates (Orange County & Shanghai)

Ian Liao is a partner in the firm’s Shanghai office. He focuses his practice on mergers and acquisitions, venture capital, and cross-border technology transactions. He has represented public and private companies in mergers, asset acquisitions and divestitures, and equity purchase transactions. 

Mr. Liao has substantial experience with M&A transactions in the internet/e-commerce space. He also has substantial experience advising venture capital funds in fund investment activities and advising high-tech companies, including start-up and pre-IPO stage companies, in fund-raising activities. In addition, he has represented clients in a number of cross-border technology licensing and intellectual property enforcement matters.


Dr. Franklin Libenson, Vice President of Global Marketing, Agendia

Dr. Franklin Libenson is Vice President of Global Marketing and LATAM Market Access. Dr. Libenson graduated from Anahuac University in Mexico City and completed his Medical Internship at Jackson Memorial Hospital in Miami, FL. He obtained his MPH from Harvard University with a concentration in Healthcare management. Dr. Libenson joined Agendia in 2010 and has over 15 years commercial and operational experience in the healthcare industry. 

 


Josh Luke, Healthcare Futurist, Hospital CEO & Faculty, USC Pride School of Public Policy

Josh Luke is a leading healthcare futurist, designing graduate-level curriculum as Adjunct Faculty for the University of Southern California’s Sol Price School of Public Policy. He serves as CSO/Senior Health Policy Analyst for Nelson Hardiman Strategy. Luke previously served as CEO of three acute hospitals, an acute rehab hospital, as Administrator for nursing homes and oversaw home health and hospice services as Vice President of Post Acute Services for a health system. Luke has a Ph.D. from the University of Nevada, and authored Readmission Prevention: Solutions Across the Provider Continuum and Ex-Acute: A former hospital CEO tells all on what’s wrong with American healthcare. Recent presentations include ACHE World Congress 2015, 2016 and 2017, keynote presentations at the Case Management Society of America’s annual meeting and USC’s C-Suite Invitational. He designed the Discharge with Dignity Guide teaching hospital case managers how to practice SNF avoidance, and attempt to discharge patients directly home from the hospital. His next book is titled Health-Wealth: Is healthcare bankrupting your business? 13 steps to take it back, being published in January 2018 from Forbes Books.


Andrew Lyon, Dean - Schmid School of Science & Technology, Chapman University

Dr. Andrew Lyon has over 20 years of experience as a chemist, educator, and entrepreneur and currently serves as the Dean of Schmid College of Science and Technology at Chapman University, a role he assumed in 2014 after spending the previous 16 years at the Georgia Institute of Technology. Dr. Lyon’s research is aimed at understanding the fundamentals of advanced polymeric assemblies, and how their unique properties can be leveraged to create new types of biomaterials for regenerative medicine applications. In addition to his role at Chapman, he serves as the Chief Scientific Officer of both Sanguina LLC and Split Rock Therapeutics, two early-stage biotechnology companies. He is the recipient of the NSF CAREER, Beckman Young Investigator, Research Corporation Research Innovation, and Camille Dreyfus Teacher-Scholar Awards, an Alfred P. Sloan Fellowship, and the National Fresenius Award. 


Jim Mazzo, Global President of Ophthalmic Devices, Zeiss 

James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers. He also heads the company’s U.S. Sales and Service Center. Mazzo is one of the ophthalmic industry’s most respected leaders with over 36 years of experience, including 22 years leading Allergan’s North American and European eye care organizations; 7 years as Chairman, President and CEO of Advanced Medical Optics (AMO); 4 years as EVP of Abbott’s global ophthalmology business; 3 years as Executive Chair and CEO of AcuFocus; has served as Board Chairman, AdvaMed. Additionally, Mazzo is Chairman of Neurotech; on the board of OCTANe, RPS, Iantech; on the University of California at Irvine foundation; Executive Committee Board Member with MDMA. 


David Mildrew, Managing Director, BioQuest

Since joining BioQuest in 2001, which was acquired by Diversified Search in 2016,  Dave Mildrew has teamed with CEOs, senior executives, and board members to find the right leaders for fast-growing healthcare organizations. His specialty is building leadership teams for emerging companies, with a mandate for fast growth. 

 

Before entering the field of executive search, Mildrew spent more than 30 years working in the healthcare industry, including in senior-level roles and as a human resources executive for global corporations including Pfizer, Medtronic, CareMark, and Tokos Medical. As Vice President, Human Resources at CareMark and Tokos, Mildrew played a key role in growing the organizations from emerging startups into large public companies. He was also instrumental in hiring the senior leaders who led IPOs and subsequent strategic acquisitions. 

 


Tom Mitro, President & COO, Aerie Pharmaceuticals

Thomas A. Mitro has served as our President and Chief Operating Officer since August 2013. From November 2012 to August 2013, Mr. Mitro served as Vice President, Sales and Marketing at Omeros Corporation, a clinical-stage biopharmaceutical company. Prior to this, Mr. Mitro was Vice President, Sales and Marketing at ISTA Pharmaceuticals from July 2002 to July 2012, where he was instrumental in building ISTA’s commercial operations and launching several eye-care products, including Bromday (bromfenac ophthalmic solution) 0.09% and Bepreve (bepotastine besilate ophthalmic solution) 1.5%. Previously, Mr. Mitro held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. Mr. Mitro received his B.S. degree from Miami University. 


Jayathi Murthy, Dean, Samueli School of Engineering, UCLA

Jayathi Y. Murthy is the Ronald and Valerie Sugar Dean at the UCLA Henry Samueli School of Engineering and Applied Science. She joined the school on January 1, 2016, becoming its seventh dean. 

Before joining UCLA Engineering, Murthy was chair of the Department of Mechanical Engineering at the University of Texas at Austin, and held the Ernest Cockrell Jr. Memorial Chair in Engineering. Consistently ranked as one of the top mechanical engineering departments in the country, the department has 66 faculty and approximately 1,500 students. 

From 2008 to 2014, Murthy served as the director of the Center for Prediction of Reliability, Integrity and Survivability of Microsystems (PRISM), a $21 million center of excellence supported by the National Nuclear Security Administration (NNSA). 

Prior to joining the University of Texas at Austin, Murthy was the Robert V. Adams Professor of Mechanical Engineering at Purdue University from 2008 to 2011. Before joining Purdue, she was a professor of mechanical engineering at Carnegie Mellon University in Pittsburgh. 

From 1988 to 1998, Murthy worked at New Hampshire-based Fluent, Inc., a developer and vendor of the world’s most widely used computational fluid dynamics software. She led the development of algorithms and software that still form the core the company’s products. 

Murthy began her career at Arizona State University, where she was an assistant professor of mechanical and aerospace engineering from 1984 to 1988. 

Her research interests include nanoscale heat transfer, computational fluid dynamics, and simulations of fluid flow and heat transfer for industrial applications. Her recent research has addressed sub-micron thermal transport, multiscale multiphysics simulations and uncertainty quantifications. 

Murthy received a Ph.D. in mechanical engineering from the University of Minnesota, an M.S. from Washington State University and a B. Tech from the Indian Institute of Technology, Kanpur. She is a fellow of the American Society of Mechanical Engineers and the author of more than 280 technical publications. She serves on the editorial boards of Numerical Heat Transfer and the International Journal of Thermal Sciences. She is an editor of the second edition of the Handbook of Numerical Heat Transfer. 


Joshua Newman, Chief Medical Officer, Salesforce

Joshua Newman, MD, MSHS, is Chief Medical Officer at Salesforce. Dr. Newman has a 20-year history in Health IT development, implementation, and strategy. He has designed, built, and managed applications, including those for medical residency administration, billing, and clinical care; to promote collaboration between physicians; and to ease the adoption of electronic medical records systems. In his current role at Salesforce, he is responsible for success across provider, payer, pharmaceutical, and medical device and diagnostics companies, and for the Salesforce Health Cloud. Prior to Salesforce, he worked as a practicing family physician and Assistant Clinical Professor of Medicine at UCLA with a research focus on health information technology.

Dr. Newman received his MD from the University of Illinois at Chicago (UIC), and completed his residency in Family Medicine at the Advocate Illinois Masonic/UIC program. He also completed a Robert Wood Johnson Clinical Scholars Program at UCLA, a postgraduate fellowship, and received an MSHS degree in Health Services.


Albert Pisano, Dean, Jacobs School of Engineering, UCSD

In his role as Dean of the Jacobs School of Engineering, Albert P. Pisano is responsible for strategic planning and programmatic development. His responsibilities include School-wide research initiatives, space plans, academic affairs, strategic planning and operations, and UC San Diego-wide cooperative initiatives. 

As Dean of the Jacobs School, Pisano holds the Walter J. Zable Chair in Engineering. He is an active researcher who serves on the faculty of the departments of mechanical and aerospace engineering and electrical and computer engineering. 

Prior to September 2013, Pisano served on the UC Berkeley faculty. The FANUC Endowed Chair of Mechanical Systems, he held faculty appointments in mechanical engineering and in electrical engineering and computer sciences. Pisano served as senior co-Director of the Berkeley Sensor & Actuator Center (an NSF Industry-University Cooperative Research Center), Director of the Electronics Research Laboratory (UC Berkeley’s largest organized research unit), and Faculty Head of the Program Office for Operational Excellence, among other leadership positions. 

In 2001, Pisano was elected to the National Academy of Engineering for contributions to the design, fabrication, commercialization, and educational aspects of MEMS. From 1997 to 1999, Pisano served as a program manager for the MEMS Program at the Defense Advanced Research Projects Agency (DARPA). 

He is a Fellow of the American Society of Mechanical Engineers, and an awardee of the Thomas Egleston Medal forDistinguished Engineering Achievement by notable alumni of Columbia University. 

Pisano earned his undergraduate (’76) and graduate degrees (’77, ’80, ’81) in mechanical engineering at Columbia University. Prior to joining the faculty at UC Berkeley, he held research positions with Xerox Palo Alto Research Center, Singer Sewing Machines Corporate R&D Center and General Motors Research Labs. 


Guruswami (Ravi) Ravichandran, Division Chair- Engineering, CalTech

Professor Ravichandran focuses on deformation and failure of materials, micro/nano mechanics, wave propagation, composites, active materials, biomaterials and cell mechanics, and experimental mechanics. Mechanics of light-weight materials; active materials with large strain actuation; space structures. 


Bob Rosenbluth, Co-Founder, Sequent Medical; President, Inceptus Medical

Bob has an extensive background of leadership, innovation, and entrepreneurship in the medical device industry. Most recently, Bob founded Inceptus Medical, a medical device incubator. Prior to Sequent, he was a founder of MicroVention, serving as President and CEO since its inception in 1997 through September 2002 and as Chairman of the Board from inception through March 2006. Prior to founding MicroVention, he founded Advanced Surgical Intervention and served in various R & D and senior management positions at Medtronic, Pfizer, and Cardiothoracic Systems. He holds a B.S. in chemical engineering from Columbia University, an M.S. in chemical engineering, and a Ph.D. in mechanical engineering from UCBerkeley.


Steve Small, Professor of Neurology and Chief Scientific Officer -Medical Innovation Institute, UCI School of Medicine

Steven L. Small, Ph.D., M.D., is Professor of Neurology, and Professor of Neurobiology and Behavior at the University of California, Irvine. He was the Chair of the Neurology from 2010-2017 and has recently become the Chief Scientific Officer of the Medical Innovation Institute. He is also Professor Emeritus at The University of Chicago. As a scientist, Dr. Small has been a pioneer in understanding the anatomy and physiology of the human brain and its relation to function by direct investigation of human subjects, particularly in speech and language. This work has encompassed the study of normal adults, typically developing children, and both adults and children with stroke. As departmental chair, Dr. Small doubled department size and expanded significantly the volume and quality of neurological services for the only academic medical center in Orange County, California, the sixth largest county in the United States.  


Rahul Soangra, Assistant Professor, Dept. of Physical Therapy, Harry & Dianne Rinker Health Sciences Campus, Chapman University

Rahul Soangra is currently an Assistant Professor in the Department of Physical Therapy at Chapman University. He is also the director of Gait Rehabilitation Research Lab. His current research projects focus on interdisciplinary applications of engineering and physical therapy principles for rehabilitation and training. Dr. Soangra’s research interests primarily focus on improving the overall quality of life of elderly patients by understanding the specific mechanisms that result in mobility and motor control limitations and by developing novel rehabilitation strategies that target those limitations. Dr. Soangra has coauthored numerous highly cited journal publications and conference articles in the field of gait and posture biomechanics. He received his B.S. and M.S. in Chemical Engineering at IIT Roorkee. He also earned M.S. in Industrial & Systems Engineering and Ph.D. in Biomedical Engineering at Virginia Tech. 


Michael Storan, Vice President, IDA Ireland

Michael Storan leads IDA Ireland’s relationships with new and existing life sciences clients on the West Coast. IDA Ireland is an agency of the Irish Government, which operates as a fully funded resource for global industries. IDA promotes Ireland as the ideal location from which to develop your International business. Michael has an MBA in International Business and has worked with IDA Ireland in California for 3 years. Prior to joining IDA, he worked in strategic roles in the technology and engineering sectors, including developing multiple public-private partnership projects


Carrie Strom, Vice President of Aesthetic and Regenerative Medicine, Allergan

Carrie Strom is the Vice President of Marketing for Allergan’s US Plastic and Regenerative Medicine business, which includes Alloderm, Artia, Strattice, Revolve, Natrelle implants and tissue expanders, and the Keller Funnel. Carrie was the commercial lead for Allergan’s acquisition and integration of LifeCell in 2017. Her current responsibilities include overseeing the downstream marketing teams, as well as contracting, reimbursement and medical education. Carrie leads the strategic direction for the portfolio in both the reconstructive and cash-pay settings, for both plastic and general surgery specialties. Carrie joined Allergan in 2011 as a Product Director on the US Urology Marketing Team to launch BOTOX Therapeutic for its first indication in Urology, and was then promoted to Senior Director of Marketing on the US Neuro-Rehab Marketing Team where she lead BOTOX Therapeutic marketing efforts and new indication planning for Spasticity and Movement Disorders. In 2014 she was promoted to VP of sales and marketing for the US Plastic Surgery business, and also assumed responsibility of marketing for SkinMedica, Allergan’s physician dispensed skincare line. Prior to joining Allergan, Carrie spent 11 years at Pfizer in roles of increasing responsibility, starting as a sales rep and moving to NYC as the Marketing Director for LIPITOR. Carrie is a member of the Board of Directors for the OC Affiliate of Susan G Komen. She lives in Corona del Mar, CA with her husband, 8 year old daughter, and 5 year old son.


Nishan Sunthares,  Chief Operating Officer, Association of British Healthcare Industries

Nishan Sunthares is Chief Operating Officer of ABHI. He is responsible for leadership of the Association, and is an Executive Director of the ABHI Board.

Nishan joined ABHI in 2010 and has overall ownership of the Association’s work programmes across its strategic priorities. Nishan’s regular, personal interaction with government Ministers, senior NHS officials and hospital Chief Executives has been key to increasing the Association’s impact. He leads the industry’s response to the increasingly challenging commercial environment. Nishan is currently involved in in engaging with NHS Improvement and local NHS leadership to ensure new models of care maximise the value and contribution from medical technologies.

After completing his degree in Medical Sciences, Nishan trained as a management accountant specialising in IT and software accounting. Nishan has worked in the medical technology industry for 15 years, and has held roles in finance, market access, as well as sales and marketing management. He serves on the Digitalhealth.London Advisory Panel and the NHS Supplier Board.


Geoff Tabin, MD, Founder, Himalayan Cataract Project

Dr. Geoff Tabin is Co-Founder and Chairman of the Himalayan Cataract Project and a Professor of Ophthalmology and Global Medicine at Stanford University. He has published more than 45 peer-reviewed articles, two books and a dozen book chapters related to his work in ophthalmology and the developing world. 

Dr. Tabin is the fourth person in the world to reach the tallest peak on each of the seven continents. His passion for mountain climbing directed him to his professional career in eye care. After summiting Mt. Everest, on one of his expeditions, he came across a Dutch team performing cataract surgery on a woman who had been needlessly blind for three years. It was then he understood his life calling. 

Tabin graduated from Yale University and then earned an MA in Philosophy at Oxford University on a Marshall Scholarship. From there, he took his interest in moral philosophy and health care delivery to Harvard Medical School where he earned his MD in 1985. After completing an ophthalmology residency at Brown University and a fellowship in corneal surgery in Melbourne, Australia, Dr. Tabin returned to Nepal to work with Dr. Sanduk Ruit. 

Tabin and Nepalese eye surgeon Dr. Sanduk Ruit established the Himalayan Cataract Project in 1995 – with a vow to work to eliminate all preventable and treatable blindness from the Himalayan region in their lifetime, a goal, in Tabin’s words, “more audacious than setting out to make the first assent of the East Face of Mount Everest.” Dr. Ruit, whom the Associated Press heralded as the “god of sight” to the world’s poor, and Tabin have proven that hospital quality standards can be applied in impoverished areas devoid of electricity and clean water. Their successful approach to restoring sight and dogged perseverance has made possible what 20 years ago seemed impossible. 

The Himalayan Cataract Project has since expanded beyond the Himalayas to encompass Sub-Saharan Africa as well. Dr.Tabin spends a considerable part of the year working abroad throughout the Himalayas and Sub-Saharan Africa.  

Tabin is a leader in both the national and international ophthalmic community. He is a member of the International Education Committee for the American Academy of Ophthalmology (AAO) and teaches a course on cataract surgery at both the AAO and the American Society of Cataract and Refractive Surgeons (ASCRS). 

The inspiring and extraordinary work of HCP Co-Founders Tabin and Ruit is the subject of the book by David Oliver Relin, SecondSuns: Two Doctors and Their Amazing Quest to Restore Sight and Save Lives (Random House). 

 


Bob Terbrueggen, CEO, DxTerity Diagnostics

Bob Terbrueggen, PhD, has nearly 20 years of experience in the genomics industry. He started his career at the Clinical Micro Sensors where he was Director of R&D and oversaw the development of the world’s first bio-electronic DNA detection platform, the e-Sensor. Following the company’s acquisition by Motorola, he became the Director of Research for Motorola Sciences. In 2005, he helped start NanoBiomics, which was named best start-up of the year by the Arizona Biotech Association and was subsequently acquired by the Molecular Profiling Institute 9 months after founding. Bob is the inventor of DxTerity’s DxDirect Technology and the principal Investigator on a major US government contract for the development and delivery of the REDI-Dx High Throughput Biodosimetry Test System. Bob double received a PhD in Chemistry from the California Institute of Technology (Caltech). He is an inventor on 22 issued US patents and more that 100 associated international patents. 


Richard Van Etten, Director, Chao Family Comprehensive Cancer Center

Dr. Richard Van Etten is a fellowship-trained hematologist and oncologist who specializes in the treatment of leukemia and other blood disorders. As director of the Chao Family Comprehensive Cancer Center, he leads a team of more than 200 physicians, scientists and other health science professionals. Van Etten's research lab studies the pathogenesis and therapy of human blood cancers, with particular emphasis on myeloid and lymphoid neoplasms that are associated with dysregulated tyrosine kinases. 

As an medical student and doctoral candidate in biophysics at Stanford University, Van Etten worked on the molecular genetics of mammalian mitochondrial DNA with biochemist David A. Clayton, PhD. After postgraduate training in internal medicine and hematology at Brigham & Women's Hospital in Boston, he was a postdoctoral fellow under Nobel laureate David Baltimore, PhD, at the Whitehead Institute in Boston.  

Van Etten went on to become a physician at Brigham & Women's Hospital and a faculty member in the departments of genetics and medicine at Harvard Medical School until 2003, when he joined Tufts University as professor of medicine. At Tufts, he held several positions, including leader of the Hematologic Malignancies Program and member of the graduate programs in Genetics, Immunology, & Molecular/Cellular Physiology at Tufts University. He assumed his first cancer center leadership role at Tufts Cancer Center in 2007 as acting associate director for clinical sciences and was appointed director in 2009. 


Brett Wall, Senior Vice President & President- Brain Therapies, Medtronic

Brett Wall serves as President of the Neurovascular business at Medtronic, which is part of the company’s Restorative Therapies Group. Brett, a seasoned medical device executive with 25 years of experience in the industry, manages a team of more than 1,000 individuals, including all business functions across all geographies. Prior to joining Medtronic, Brett served as Covidien’s President, Neurovascular and International, where he managed all commercial activities and functions of the business resulting in a doubling of revenue from 2011 to 2015. Previously, Brett served as Senior Vice President and President, Neurovascular and Senior Vice President and President, International at ev3, Inc. From 2000 to 2008, Brett held positions of Vice President, Marketing for the Neurovascular and Peripheral Vascular divisions at Micro Therapeutics until its merger with ev3.

Previously, Brett worked at Boston Scientific as the Director of Marketing, Cardiovascular, Asia Pacific and Marketing Manager, Japan, where he was responsible for the Interventional Cardiology product lines within the Asia-Pacific region. Brett’s career in the medical device industry has also featured positions of increasing responsibility at C.R. Bard, where he was responsible for marketing the company’s entire suite of urological products.

Brett currently serves on the board executive committee for OCTANe, a group that promotes technical growth and expertise in the greater Orange County, California area. He is also a member of the CEO Roundtable at the University of California, Irvine. Previously, Brett served as Chairman of the Heart and Stroke Ball for the American Heart Association, Orange County Chapter. Brett earned his bachelor’s degree in Comprehensive Business Administration with an emphasis in Marketing from the University of Nebraska at Kearney. He is a resident of Southern California.


Congresswoman Mimi Walters, U.S. Representative (R-CA 45th District)

Congresswoman Mimi Walters represents the 45th Congressional District of California and currently serves on the House Energy and Commerce Committee. She previously served in the California State Senate from 2008-2014, where she represented California's 37th State Senate District.  Prior to serving in the Senate, she served two two-year terms in the State Assembly. 

Mimi began her career in public service as a member of the Laguna Niguel City Council in 1996, where she was a leading voice for fiscally responsible government and local control. She also served as the City’s mayor in 2000. 

Mimi possesses a background in both business and local government. Her professional career has included time with the firm of Drexel, Burnham & Lambert as an Investment Executive, and Kidder Peabody & Company. 

She is a founder of the California Women’s Leadership Association (CWLA) and has served on the Boards of the National Association of Women Business Owners (NAWBO), the Laguna Niguel Republican Women Federated, the American Cancer Society, and the South Coast Medical Center Foundation. 

A champion for job creation, lower taxes, less intrusive government, and fiscal responsibility, Mimi has been active in conservative causes for many years. In 2006, she led the fight against eminent domain abuse by serving as the Honorary Statewide Chair for the Protect Our Homes Coalition. The Orange County Republican Party has awarded her with three honors: Local Elected Official of the Year in 1997; Volunteer of the Year in 1998; and Legislator of the Year in 2005.  

In the State Senate, she served as Vice Chair of the Senate Committees on Appropriations and Public Employment & Retirement. She also served as a member of the Senate Budget and Fiscal Review Committee. 

Mimi graduated from the University of California at Los Angeles in 1984 with a Bachelor of Arts degree in Political Science. She and her husband, David, have four children. 


Gregory Washington, Dean, Samueli School of Engineering, UCI 

Dean Gregory N. Washington, Ph.D., joined The Samueli School of Engineering in August 2011. Under his leadership, the school has increased its faculty ranks and numbers of students. He instituted a popular freshman experiential learning program that gives engineering students a taste of real-world product development. He also secured a $9.5 million gift in support of the school's efforts to engage a more diverse student population through STEM outreach. 

Prior to his arrival at UCI, Washington served as the interim dean for the College of Engineering at The Ohio State University. As a professor of mechanical engineering, Washington has been involved in multi-domain research for the last 20 years. His core area of interest lies in the area of dynamic systems, with an emphasis on modeling and control of smart material systems and devices. He has been involved in the design and control of mechanically actuated antennas, advanced automotive systems incorporating smart materials, hybrid electric vehicles, and structural position and vibration control with smart materials. 

He has conducted research for a host of organizations including the National Science Foundation, NASA, General Motors Co., the Air Force Research Laboratory and the U.S. Army Research Office. Washington has served as a member of the U.S. Air Force Scientific Advisory Board, NSF Engineering Advisory Committee, Institute for Defense Analyses and numerous other boards. 

Washington is a recipient of the NSF Faculty Early Career Development (CAREER) Award and a Fellow of the American Society of Mechanical Engineers. Currently, he is the vice chair of the Engineering Deans Council of the American Society for Engineering Education (ASEE). He holds bachelor's, master's and doctoral degrees in mechanical engineering from North Carolina State University. 


Scott Whitaker, CEO, AdvaMed

Scott Whitaker is President and CEO of AdvaMed, the world’s largest medical technology association. AdvaMed members make the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments, to help people live longer, healthier lives. AdvaMed members range from the largest to the smallest medical technology innovators and companies. 

As CEO of AdvaMed, Whitaker is the voice of the medical technology industry. He is widely recognized as a top health care advocate and policy expert with experience across multiple health policy sectors, having worked successfully with diverse stakeholder groups – including hospital, patient and physician groups, regulators, public and private payers, and global trade organizations – to advance medical technology innovation and timely patient access to next-generation treatments and cures. 

Prior to AdvaMed, Whitaker was chief operating officer of the Biotechnology Innovation Organization (BIO), the world’s largest trade association representing biotechnology companies, and president of the BIO International Convention, the world’s largest biotech conference. Having served as COO of BIO since 2005, Whitaker brings a deep knowledge of the medical technology innovation ecosystem, a wealth of health care advocacy expertise, and strong working relationships with patient groups and other industry stakeholders. 

Whitaker also previously served as chief of staff of the U.S. Department of Health & Human Services (HHS) – a cabinet agency with 67,000 employees and a budget of $550 billion – from 2003 to 2005. As HHS chief of staff, Whitaker managed the day-to-day operations of the department; led the department’s activities on all major policy and management issues and initiatives; and served as the top liaison to the White House on policy, management and political matters. He also served as assistant secretary for legislation at HHS from 2001 to 2003. Whitaker began his Washington career on Capitol Hill, where he worked for U.S. Senator Don Nickles (R-Okla.). 

Whitaker holds a master’s degree in government from Johns Hopkins University and a degree in political science from Palm Beach Atlantic University. 


Scott Whitcup, CEO, Akrivista & Whitecap Biosciences

Dr. Scott M. Whitcup has been Executive Vice President, Research and Development, and Chief Scientific Officer since April 2009. Prior to that, Dr. Whitcup was Executive Vice President, Research and Development since July 2004. Dr. Whitcup joined Allergan in January 2000 as Vice President, Development, Ophthalmology. In January 2004, Dr. Whitcup became Allergan's Senior Vice President, Development, Ophthalmology. From 1993 until 2000, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup's leadership was vital in building the clinical research program and promoting new ophthalmic therapeutic discoveries. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles. Dr. Whitcup serves on the board of directors of Semnur Pharmaceuticals, a privately-held company. Dr. Whitcup is a former member of the board of directors of Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. Dr. Whitcup graduated from Cornell University and Cornell University Medical College. He completed residency training in internal medicine at the University of California, Los Angeles and in ophthalmology at Harvard University, as well as fellowship training in uveitis and ocular immunology at the National Institutes of Health. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles. 


Tom Wilder, Former CEO, Sequent Medical; CEO, Neuros Medical

Since August 2017, Tom has served as the President and Chief Executive Officer of Neuros Medical, Inc., a neuromodulation company.  Prior to joining Neuros, he led Sequent Medical, Inc., a neurovascular company that developed the WEB Aneurysm Embolization System, for six years.  Sequent was acquired by Terumo Corporation in 2016 for up to $380 million.  From 2006 to 2009, Tom served as President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients.  From 2002 to 2006, he served as President and CEO of MicroTherapeutics, Inc. (MTIX), a company also focused on the neurovascular space, that was merged in 2006 into ev3, Inc. (EVVV) at a valuation of $360 million.  From 1991 to 2002, Tom served in positions of increasing responsibility at Medtronic, Inc. (MDT), most recently as Vice President and General Manager of its endovascular stent grafts division.  Tom currently serves on the Board of Directors of Penumbra, Inc. (PEN) and Endologix, Inc. (ELGX).  He received a B.A. from Stanford University and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management. 

 


Clay Wilemon, CEO & Chief Strategy Officer, DevicePharm

Clay Wilemon is the Chief Executive Officer and Chief Strategy Officer at DevicePharm, Inc. Wilemon has 25 years of experience in medical device marketing with both early-stage companies and global healthcare leaders. He serves as Interim Chair of Tenex Health, Inc. and is an Independent Board of Governors of Sonex Health, LLC.


Yannis Yortsos, Dean, Viterbi School of Engineering, USC

Yannis Yortsos is Dean of the USC Viterbi School of Engineering. He is the Chester F. Dolley Professor of Chemical and Petroleum Engineering, and holds the Zohrab A. Kaprielian Dean’s Chair in Engineering. He is well known for his work on fluid flow, transport and reaction processes in porous and fractured media with applications to the recovery of subsurface fluids and soil remediation. He is a member of the US  National Academy, an Associate member of the Academy of Athens and one of the co-founders of the NAE Grand Challenges Scholars Program.